LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ)
$10.54 -0.375 (-3.4356%)
Analysed LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) News Sources
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
29-04-2026
yahoo.com
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
01-05-2026
yahoo.com
Lexaria Updates Progress on Human Study #7
05-05-2026
yahoo.com
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
03-06-2026
yahoo.com
LEXX: Animal & Human GLP-1 Studies Continue
15-06-2026
yahoo.com
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
17-06-2026
yahoo.com
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
23-06-2026
yahoo.com
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
25-06-2026
yahoo.com
LEXX: Dosing Started for Animal & Human GLP-1 Studies
17-07-2026
yahoo.com
Lexaria Enters a Material Transfer Agreement With PegBio
13-08-2026
yahoo.com
What is the current price of LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ)?
The current price of LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) is $10.54.
LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) absolute price change since previous trading day?
The absolute price change of LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) since the previous trading day is $-0.375.
LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) percentage price change since previous trading day?
The percentage price change of LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) since the previous trading day is -3.4356%.
What is the most recent average sentiment score for LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ)?
The most recent average sentiment score for LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ)?
The most recent sentiment for LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) is .
SEC-8K** Filing Available For LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.